论文部分内容阅读
目的探讨EB病毒NA1-IgA和VCA-IgA抗体与鼻咽癌的诊断和治疗效果的相关性。方法使用酶联免疫吸附试验(ELISA)测定124例治疗前和治疗后鼻咽癌患者以及173例正常体检人群血清EB病毒NA1-IgA和VCA-IgA抗体。结果单项检测时EB病毒检测的敏感性和准确性分别为:NA1-IgA 88.7%、91.2%,VCA-IgA75.8%、84.8%,两者联合检测的敏感性和准确性分别为97.6%、93.3%。鼻咽癌患者血清EBNA1-IgA抗体rA值和阳性率在临床各期(Ⅰ期阳性率除外)治疗前后均无统计学差异(P>0.05),而鼻咽癌患者血清EBVCA-IgA抗体rA值和阳性率在临床各期(Ⅳ期除外)治疗后均比治疗前有显著下降(P<0.05)。结论两项指标联合检测可提高早期鼻咽癌诊断的敏感性和准确性。血清EB病毒NA1-IgA抗体水平和阳性率基本与治疗效果无关.VCA-IgA抗体水平和阳性率与治疗呈明显的相关性,可作为鼻咽癌疗效判断以及监测病情和预后的重要指标。
Objective To investigate the correlation between Epstein-Barr virus NA1-IgA and VCA-IgA antibodies and the diagnosis and treatment of nasopharyngeal carcinoma. Methods Serum Epstein-Barr virus NA1-IgA and VCA-IgA antibodies were detected in 124 patients with nasopharyngeal carcinoma and 173 normal controls before and after treatment by enzyme-linked immunosorbent assay (ELISA). Results The sensitivity and accuracy of detection of Epstein-Barr virus (EBV) were 88.7% and 91.2% for NA1-IgA and 75.8% and 84.8% for VCA-IgA, respectively. The sensitivity and accuracy of the two methods were 97.6% 93.3%. The serum rA value and positive rate of EBNA1-IgA antibody in nasopharyngeal carcinoma patients had no statistical difference (P> 0.05) before and after the treatment in all stages (except the positive rate of stage I), while the rA value of serum EBVCA-IgA antibody in patients with nasopharyngeal carcinoma And positive rate in the clinical stage (except for stage Ⅳ) were significantly lower than before treatment (P <0.05). Conclusion Combined detection of two indexes can improve the sensitivity and accuracy of early diagnosis of nasopharyngeal carcinoma. Serum Epstein-Barr virus NA1-IgA antibody level and positive rate basically has nothing to do with the treatment effect.VCA-IgA antibody level and positive rate was significantly correlated with the treatment, can be used as nasopharyngeal cancer to determine the efficacy and prognosis of an important indicator.